There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Tricida Inc. (TCDA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.61, or -6.09%, to $9.4. Volume reached 6,344 shares, with price reaching a high of $9.49 and a low of $9.4. Recently, Yahoo Finance discussed the stock, revealing that Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference.
As a NASDAQ listed company, TCDA falls under the Healthcare sector while operating within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $9.49 and fluctuated between $10.01 as its day high and $9.10 as its day low. The current market capitalization of Tricida Inc. is $547.48M. A total of 1.82 million shares were traded on the day, compared to an average of 592.55K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, TCDA has seen 17 BUY and 9 SELL insider trades, representing the acquisition of 837,862 and the disposition of 284,939 shares. Over the last 12 months, there were 32 BUYs and 31 SELLs from insiders. Insiders purchased 3,385,327 shares during that period but sold 6,897,600.
In the most recent transaction, Venrock Healthcare Capital Par bought 473,459 shares of TCDA for 11.40 per share on Sep 07. After the transaction, the 10% Owner now owns 8,294,663 company shares. In a previous transaction on Sep 06, Venrock Healthcare Capital Par bought 150,223 shares at 11.43 per share. TCDA shares that 10% Owner owns now total 7,821,204.
Among the insiders who bought shares, Venrock Healthcare Capital Par acquired of 63,030 shares on Sep 02 at a per-share price of $12.76. This resulted in the 10% Owner holding 7,670,981 shares of TCDA after the transaction. In another insider transaction, Venrock Healthcare Capital Par bought 50,000 shares at $12.20 per share on Aug 30. Company shares held by the 10% Owner now total 7,607,951.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for TCDA in the last 3 months, the mean price target is $16.50 with high estimates of $20.00 and low estimates of $8.00. In terms of 52-week highs and lows, TCDA has a high of $13.85 and a low of $4.10.
As of this writing, TCDA has an earnings estimate of $-0.54 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of $-0.52 per share and a lower estimate of $-0.55. The company reported an EPS of $-0.49 in the last quarter, which was 5.77% higher than expectations of $-0.52.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TCDA is Buy with a score of 4.33. A total of 3 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.